Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. Their proprietary DELigase™ platform enables the discovery of therapies that can either degrade or elevate protein levels, offering potential treatments for a wide range of diseases. Nurix is advancing a pipeline of internally developed and partnered programs, targeting historically challenging drug targets.
The headquarters serves as the central hub for research and development, corporate strategy, clinical operations, and administrative functions.
The facility is equipped with state-of-the-art laboratories for drug discovery and development, including capabilities for high-throughput screening and protein engineering, situated within a modern life sciences campus.
Nurix fosters a science-driven, innovative, and collaborative work environment. Employees are typically passionate about advancing medical science and bringing new therapies to patients with unmet needs. The culture emphasizes teamwork, intellectual curiosity, and a fast-paced approach to research.
The San Francisco headquarters places Nurix at the epicenter of biotech innovation, facilitating access to top talent, research institutions, and venture capital, crucial for its growth and development of novel therapeutics.
While headquartered in San Francisco, USA, Nurix Therapeutics conducts global clinical trials for its drug candidates. Its collaborations with international pharmaceutical companies like Sanofi and Gilead also extend its research and potential commercial reach worldwide. The company aims to develop therapies that can address patient needs globally.
1700 Owens Street, Suite 205
San Francisco
CA
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Nurix Therapeutics' leadership includes:
Nurix Therapeutics has been backed by several prominent investors over the years, including:
Nurix Therapeutics has seen strategic additions to its leadership team in the past year, particularly strengthening its clinical and business development functions to support pipeline advancement and corporate growth. No major C-suite departures have been publicly announced recently.
Discover the tools Nurix Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Nurix Therapeutics primarily utilizes the email format [first_initial][last]@nurixtx.com. This is a common format for companies in the biopharmaceutical industry.
[first_initial][last]@nurixtx.com
Format
jsmith@nurixtx.com
Example
85%
Success rate
GlobeNewswire • May 28, 2024
Nurix Therapeutics announced that its President and CEO, Arthur T. Sands, M.D., Ph.D., will present at the Jefferies Healthcare Conference on June 5, 2024. The presentation will likely cover company progress and pipeline updates....more
GlobeNewswire • May 13, 2024
Nurix reported its Q1 2024 financial results, highlighting progress in its clinical programs, including NX-5948 for B-cell malignancies and NX-2127 for various B-cell cancers. The company also discussed upcoming milestones and its financial position....more
GlobeNewswire • April 8, 2024
Nurix presented positive updated data from its Phase 1a trial of NX-5948 in patients with relapsed/refractory CLL, showing promising efficacy and a favorable safety profile. The data supports further development of this BTK degrader....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Nurix Therapeutics, are just a search away.